Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02856750 · ClinicalTrials.gov registry record · Early Phase 1

Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures

A Early Phase 1 study of Acute Pain, sponsored by Denver Health and Hospital Authority.

Completed
Registry status
Early Phase 1
Development phase
100
Enrollment target
1
Study location

NCT02856750 is a Early Phase 1 study of Acute Pain that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 100 participants, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02856750, a Early Phase 1 study of Acute Pain, has completed, sponsored by Denver Health and Hospital Authority.

COMPLETED
Registry status
Early Phase 1
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

A Multi-center, Randomized Controlled Trial of the Efficacy of Gabapentin vs. Placebo for Adjutant Pain Control Following Acute Rib Fractures.

Conditions Studied

Interventions

  • DRUG Gabapentin

Study Locations (1)

Colorado

  • Denver Health Medical Center - Denver

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2016-10
Est. Completion 2018-10-23
Phase Early Phase 1

What the Registry Record Tells You About NCT02856750

The ClinicalTrials.gov registry entry for NCT02856750 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 266-participant average among 50 other Acute Pain trials with a reported enrollment target (62% lower). The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 1 intervention - of which Gabapentin is the first listed.

NCT02856750 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT02856750 about?

NCT02856750 is a clinical study titled "Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures". A Multi-center, Randomized Controlled Trial of the Efficacy of Gabapentin vs. Placebo for Adjutant Pain Control Following Acute Rib Fractures.

What is the current status of trial NCT02856750?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2016-10. Estimated completion is 2018-10-23.

What conditions does trial NCT02856750 study?

This clinical trial studies the following conditions: Acute Pain.

What interventions are being tested in trial NCT02856750?

The interventions under investigation include: Gabapentin (DRUG).

Who is sponsoring clinical trial NCT02856750?

This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02856750 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.